Safety and Efficacy of Allopurinol in Chronic Kidney Disease

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1507-1516

  Thurston, Maria Miller ^a   Phillips, Beth Bryles ^b   Bourg, Catherine A ^b  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

adverse effects; allopurinol; allopurinol hypersensitivity syndrome; chronic kidney disease; efficacy; renal; safety

Indexed keywords

ALLOPURINOL; OXIPURINOL; URIC ACID;

CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GOUT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

ADVERSE EFFECTS; ALLOPURINOL; ALLOPURINOL HYPERSENSITIVITY SYNDROME; CHRONIC KIDNEY DISEASE; EFFICACY; RENAL; SAFETY;

ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84889048135     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013504740     Document Type: Review

References (30)

1. Zhu Y,Pandya BJ,Choi HK.Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008.Arthritis Rheum. 2011;63:3136-3141.
2. Neogi T.Clinical practice: gout.N Engl J Med. 2011;364:443-452.
3. Kersley GD.Long-term use of allopurinol in the treatment of gout.Ann Rheum Dis. 1970;29:89-92.
4. Zyloprim (allopurinol) [product information]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2298ed2a-e01b-4f7c-9902-7c58a6e06b7a. Accessed October 9, 2012.
5. Abdellatif AA,Elkhalili N.Management of gouty arthritis in patients with chronic kidney disease.Am J Ther. 2012;:.
6. Fuldeore MJ,Riedel AA,Zarotsky V,Pandya BJ,Dabbous O,Krishnan E.Chronic kidney disease in gout in a managed care setting.BMC Nephrol. 2011;12:36.
7. Curiel RV,Guzman NJ.Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.Semin Arthritis Rheum. 2012;42:166-178.
8. El-Zawawy H,Mandell BF.Managing gout: how is it different in patients with chronic kidney disease?.Cleve Clin J Med. 2010;77:919-928.
9. Aronoff GR,Bennett WM,Berns JS, et alDrug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.Philadelphia, PA: American College of Physicians; 2007:.
10. Hande KR,Noone RM,Stone WJ.Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.Am J Med. 1984;76:47-56.
11. Jordan KM,Cameron JS,Snaith M,et al.British society for rheumatology and British health professionals in rheumatology guideline for the management of gout.Rheumatology (Oxford). 2007;46:1372-1374.
12. Zhang W,Doherty M,Bardin T,et al.EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT).Ann Rheum Dis. 2006;65:1312-1324.
13. Khanna D,Fitzgerald JD,Khanna PP,et al.2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.Arthritis Care Res (Hoboken). 2012;64:1431-1446.
14. Khanna D,Khanna PP,Fitzgerald JD,et al.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Arthritis Care Res (Hoboken). 2012;64:1447-1461.
15. Dalbeth N,Stamp L.Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.Semin Dial. 2007;20:391-395.
16. Panomvana D,Sripradit S,Angthararak S.Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.J Clin Rheumatol. 2008;14:6-11.
17. Chao J,Terkeltaub R.A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.Curr Rheumatol Rep. 2009;11:135-140.
18. Stamp LK,Taylor WJ,Jones PB,et al.Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.Arthritis Rheum. 2012;64:2529-2536.
19. Stamp LK,O'Donnell JL,Zhang M,et al.Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.Arthritis Rheum. 2011;63:412-421.
20. Jung JW,Song WJ,Kim YS,et al.HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.Nephrol Dial Transplant. 2011;26:3567-3572.
21. Tassaneeyakul W,Jantararoungtong T,Chen P,et al.Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.Pharmacogenet Genomics. 2009;19:704-709.
22. Lonjou C,Borot N,Sekula P,et al.A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.Pharmacogenet Genomics. 2008;18:99-107.
23. Hung SI,Chung WH,Liou LB,et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc Natl Acad Sci U S A. 2005;102:4134-4139.
24. Ryu HJ,Song R,Kim HW,et al.Clinical risk factors for adverse events in allopurinol users.J Clin Pharmacol. 2013;53:211-216.
25. Vazquez-Mellado J,Morales EM,Pacheco-Tena C,Burgos-Vargas R.Relation between adverse events associated with allopurinol and renal function in patients with gout.Ann Rheum Dis. 2001;60:981-983.
26. Khanna D,Pandya BJ,D'Souza AO,Meissner BL,Kamalakar R,Harikrishnan V.Incidence of allopurinol hypersensitivity syndrome (AHS) among renally impaired patients [abstract].Arthritis Rheum. 2009 2043;60:.
27. Dalbeth N,Kumar S,Stamp L,Gow P.Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.J Rheumatol. 2006;33:1646-1650.
28. Paisansinsup T,Breitenstein MK,Schousboe JT.Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol.J Clin Rheumatol. 2013;19:180-186.
29. Badve SV,Brown F,Hawley CM,et al.Challenges of conducting a trial of uric-acid-lowering therapy in CKD.Nat Rev Nephrol. 2011;7:295-300.
30. Graham GG,Kannangara DRW,Stocker SL,et al.Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.Br J Clin Pharmacol. 2013;:.